Aeglea Biotherapeutics, Inc. (AGLE)
Stock Price:
$7.66 USD
-0.19 (-2.42%)
Updated Oct 28, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
341.63M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-83.21M |
| Shares Out |
44.60M |
| EPS (ttm) |
-2.19 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 28, 2020 |
| Last Price |
$7.66 |
| Previous Close |
$7.85 |
| Change ($) |
-0.19 |
| Change (%) |
-2.42% |
| Day's Open |
7.58 |
| Day's Range |
7.43 - 7.81 |
| Day's Volume |
113,296 |
| 52-Week Range |
3.50 - 11.38 |
More Stats
| Market Cap |
341.63M |
| Enterprise Value |
187.33M |
| Earnings Date (est) |
Nov 4, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
44.60M |
| Float |
36.91M |
| EPS (basic) |
-2.28 |
| EPS (diluted) |
-2.19 |
| FCF / Share |
-1.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.84M |
| Short Ratio |
10.55 |
| Short % of Float |
7.70% |
| Beta |
1.82 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.25 |
| Revenue |
n/a |
| Operating Income |
-84.64M |
| Net Income |
-83.21M |
| Free Cash Flow |
-78.64M |
| Net Cash |
154.31M |
| Net Cash / Share |
3.46 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-36.43% |
| ROE |
-66.08% |
| ROIC |
-135.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (8)
| Buy |
7 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$16.00*
(108.88% upside)
Low
10.0
Current: $7.66
High
26.0
Target: 16.00
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|
| Revenue | - | 3.89 | 5.21 | 4.63 | 6.09 | - |
| Revenue Growth | - | -25.3% | 12.47% | -23.94% | - | - |
| Gross Profit | - | 3.89 | 5.21 | 4.63 | 6.09 | - |
| Operating Income | -80.33 | -45.46 | -27.68 | -21.91 | -11.32 | -8.90 |
| Net Income | -78.25 | -44.35 | -27.24 | -21.70 | -11.30 | -10.35 |
| Shares Outstanding | 31.95 | 20.82 | 15.13 | 9.79 | 0.60 | 0.17 |
| Earnings Per Share | -2.45 | -2.13 | -1.80 | -2.22 | -19.21 | - |
| Operating Cash Flow | -65.69 | -32.19 | -24.62 | -18.84 | -10.98 | -7.34 |
| Capital Expenditures | -1.49 | -0.42 | -0.62 | -0.21 | -0.21 | -0.18 |
| Free Cash Flow | -67.18 | -32.62 | -25.23 | -19.05 | -11.19 | -7.52 |
| Cash & Equivalents | 73.45 | 74.51 | 50.30 | 63.50 | 33.14 | 2.66 |
| Total Debt | 5.06 | - | - | - | - | - |
| Net Cash / Debt | 68.39 | 74.51 | 50.30 | 63.50 | 33.14 | 2.66 |
| Assets | 83.18 | 77.74 | 56.08 | 67.06 | 38.65 | 2.93 |
| Liabilities | 23.10 | 10.31 | 5.74 | 4.10 | 2.55 | 1.06 |
| Book Value | 60.08 | 67.43 | 50.34 | 62.97 | -22.21 | -11.47 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aeglea Biotherapeutics, Inc. |
| Country |
United States |
| Employees |
83 |
| CEO |
Anthony G. Quinn |
Stock Information
| Ticker Symbol |
AGLE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: AGLE |
| IPO Date |
April 7, 2016 |
Description
Aeglea BioTherapeutics, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic and cancer diseases. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme which is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. Its preclinical pipeline products comprise ACN00177, a product candidate for the treatment of homocystinuria; AEB5100, a recombinant human enzyme that degrades plasma cystine and cysteine; AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine; and AEB3103, a product candidate. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.